Laekna, a global biotechnology company specializing in metabolic and cancer drug development, has partnered with Eli Lilly and Company to expedite the development of LAE102. This novel Activin Receptor Type 2A (ActRIIA) antagonistic monoclonal antibody (mAb) targets muscle-preserving weight loss in individuals with obesity. This collaboration aims to address the global obesity epidemic and improve the lives of those affected.

The partnership centers on the development and clinical evaluation of LAE102, a potential first-in-class therapy for obesity. ActRIIA plays a vital role in muscle regeneration and lipid metabolism. Pre-clinical models have demonstrated LAE102’s ability to increase lean mass and decrease fat mass simultaneously. When combined with a GLP1R agonist, LAE102 shows promise in further reducing fat mass while regaining lean mass often lost with GLP1R agonist treatment. This suggests LAE102 may be a valuable addition to existing weight management strategies, offering a more comprehensive approach to weight control. By merging Laekna’s innovative research with Lilly’s extensive experience in metabolic diseases, the collaboration strives to elevate the standard of care for obesity. Lilly will leverage its Catalyze360-ExploR&D platform to accelerate LAE102’s development.

LAE102, discovered by Laekna, targets ActRIIA, a key receptor in muscle regeneration and lipid metabolism. Pre-clinical studies show LAE102 increases lean mass while decreasing fat mass. Combined with a GLP1R agonist, it further reduces fat mass and restores lean mass lost through GLP1R agonist treatment. This makes LAE102 a promising candidate for quality weight control, focusing on fat reduction while preserving muscle. The potential of blocking the Activin-ActRII pathway lies in promoting muscle regeneration and decreasing fat mass. Laekna is developing additional drug candidates, including LAE103 (an ActRIIB-selective antibody) and LAE123 (a dual ActRIIA/IIB inhibitor), to maximize the therapeutic potential of targeting ActRII receptors.

Source link: http://www.businesswire.com/news/home/20241120291603/en/Laekna-Announces-a-Clinical-Collaboration-with-Lilly-to-Develop-LAE102-a-Novel-Monoclonal-Antibody-Targeting-Activin-Receptor-Type-2A-for-The-Treatment-of-Obesity

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.